Cardiome/Astellas Schedule Kynapid Meeting With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Meanwhile, Astellas yanks its Canadian new drug submission for the atrial fibrillation candidate to align its North American regulatory strategy.